Boston Pharma Appoints Santiago Arroyo, M.D., Ph.D., As Chief Medical Officer And Constantine Chinoporos, As Chief Business Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Boston Pharmaceuticals, a new fully integrated drug development company offering an innovative alternative model for drug development commercializiation, today announced the appointment of Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer and Constantine Chinoporos, as Chief Business Officer. Both will work with senior leadership at the company to identify and partner with academic, biotechnology and biopharmaceutical groups to acquire clinical assets at various stages of their development and bring them to market.

Suggested Articles

The financing sets AM-Pharma up to advance in sepsis-associated acute kidney injury independently now Pfizer has turned down its option to buy.

The FDA sent Eton's partner, Bausch Health, a complete response letter that raised “no concerns” about the clinical data in the drug’s application.

A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.